Systematic Review and Meta-Analysis of Second-Generation Sham-Controlled Randomized Trials of Renal Denervation Therapy for Patients with Hypertension.

Autor: Dantas CR; Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina. claradantasbaires@gmail.com., De Oliveira Macena Lôbo A; Universidade Federal de Pernambuco, Recife, Brazil., De Almeida AM; Universidade Federal de Mato Grosso, Mato Grosso, Brazil., De Moraes FCA; Federal University of Pará, Altamira, Brazil., Sano VKT; Federal University of Acre, Rio Branco, Brazil., Kelly FA; Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2024 Nov; Vol. 31 (6), pp. 669-676. Date of Electronic Publication: 2024 Oct 12.
DOI: 10.1007/s40292-024-00675-9
Abstrakt: Introduction: Renal denervation has been associated with substantial and sustained blood pressure reduction and is considered to serve as an alternative treatment for patients with resistant hypertension. However, the first published SHAM-controlled trial assessing RDN safety and efficacy showed no difference between groups.
Aim: We aimed to perform a meta-analysis quantifying the magnitude of blood pressure decrease secondary to renal denervation in patients with resistant hypertension.
Methods: Databases were searched for RCTs that compared RDN therapy to SHAM procedure and reported the outcomes of (1) 24-hour ambulatory blood pressure; (2) Office systolic blood pressure; (3) Daytime systolic blood pressure; and (4) Night-time systolic blood pressure. Mean differences with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was examined with I² statistics. P values of < 0.05 were considered statistically significant. Statistical analyses were performed using RStudio 4.2.3.
Results: Nine studies and 1622 patients were included. The AMBP [MD -3.72 95%CI -5.44, -2.00 p < 0.001; I²=34%] and DSBP [MD -4.10 95%CI -5.84, -2.37 p < 0.001; I²=0%] were significantly reduced in the RDN arm. ODBP [MD -6.04 95%CI -11.31, -0.78 p = 0.024; I²=90%] and NSBP [MD -1.81 95%CI -3.90, 0.27 p = 0.08; I²=0%] did not reach a statistically significant difference between groups.
Conclusion: Renal denervation demonstrates greater efficacy in reducing 24-hour ambulatory and daytime systolic blood pressure in patients diagnosed with resistant hypertension.
Competing Interests: Declarations. Ethical approval: Not applicable. Consent for publication: Not applicable. Conflict of interest: The authors declare no competing interest.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: